Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.
In an open, randomized, triple crossover study, the effects of cisapride and sucralfate on the pharmacokinetics of sparfloxacin were assessed. Fifteen healthy volunteers received 400 mg of sparfloxacin as a single oral dose on day 0. In a random order, concomitant doses of 10 mg of cisapride three times daily from day -2 to day 2 and 1 g of sucralfate four times daily from day -2 to day 0 were administered. Sparfloxacin concentrations were measured by bioassay and high-performance liquid chromatography. Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6. For the cisapride group there was a significant decrease in the sparfloxacin T(max) (1.9 +/- 2.1 h) and a significant increase in C(max) (1.74 +/- 0.73 microg/ml). The QTc interval for patients receiving sparfloxacin and cisapride was prolonged by 7.7% compared to the QTc interval during medication-free periods. Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%. Concomitant adminstration of cisapride accelerates the absorption and increases the peak concentration of sparfloxacin without having a significant effect on the extent of bioavailability. Coadministration of sucralfate leads to a 44% decrease in the bioavailability of sparfloxacin.
Zix
J A
JA
Department of Pulmonary and Infectious Diseases, City Hospital Zehlendorf-Heckeshorn, Freie Universitat Berlin, Germany.
Geerdes-Fenge
H F
HF
Rau
M
M
Vöckler
J
J
Borner
K
K
Koeppe
P
P
Lode
H
H
D000328:Adult; D000890:Anti-Infective Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D020117:Cisapride; D018592:Cross-Over Studies; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D010880:Piperidines / Q000494:pharmacology*; D015363:Quinolones / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D013392:Sucralfate / Q000494:pharmacology*
D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; D024841:Fluoroquinolones; D010880:Piperidines; D015363:Quinolones; D013392:Sucralfate; C061363:sparfloxacin; D020117:Cisapride